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Abstract
Introduction: The development of reproducible methods for deriving human embryonic stem cell (hESC) lines in
compliance with good manufacturing practice (GMP) is essential for the development of hESC-based therapies.
Although significant progress has been made toward the development of chemically defined conditions for the
maintenance and differentiation of hESCs, efficient derivation of new hESCs requires the use of fibroblast feeder
cells. However, GMP-grade feeder cell lines validated for hESC derivation are not readily available.
Methods: We derived a fibroblast cell line (NclFed1A) from human foreskin in compliance with GMP standards.
Consent was obtained to use the cells for the production of hESCs and to generate induced pluripotent stem cells
(iPSCs). We compared the line with a variety of other cell lines for its ability to support derivation and self-renewal
of hESCs.
Results: NclFed1A supports efficient rates (33%) of hESC colony formation after explantation of the inner cell mass
(ICM) of human blastocysts. This compared favorably with two mouse embryonic fibroblast (MEF) cell lines.
NclFed1A also compared favorably with commercially available foreskin fibroblasts and MEFs in promoting
proliferation and pluripotency of a number of existing and widely used hESCs. The ability of NclFed1A to maintain
self-renewal remained undiminished for up to 28 population doublings from the master cell bank.
Conclusions: The human fibroblast line Ncl1Fed1A, produced in compliance with GMP standards and qualified for
derivation and maintenance of hESCs, is a useful resource for the advancement of progress toward hESC-based
therapies in regenerative medicine.
Introduction
Progress in the use of human embryonic stem cells
(hESCs) derivatives for cellular therapies will require the
production of clinical-grade lines under the control of
good manufacturing practice (GMP) [1]. The ultimate
goal is to increase reproducibility in the production of
hESCs by developing chemically defined culture condi-
tions by using recombinant proteins for hESC derivation
and culture. A major hurdle is to dispense with the use
of feeder cells, which are conventionally used to pro-
mote and support hESC self-renewal [2]. However, the
ability of feeder-free culture systems to maintain genetic
stability remains controversial [3]. Furthermore, repro-
ducible techniques for deriving new GMP-grade hESC
lines from human blastocysts without the use of feeder
cells remain to be developed [4]. To date, only a single
report describes successful hESC derivation in the
absence of feeder cells [5]. Interestingly, the two lines
derived under these conditions acquired karyotypic
abnormalities during subsequent culture [5]. Thus, in
the absence of a chemically defined, GMP-compliant
method for efficient derivation of hESCs, the production
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of new clinical-grade hESC lines will require a supply of
GMP-grade feeder cells.
The use of fibroblast cells as feeder cells for derivation
and long-term culture of hESCs has been well documen-
ted [2,6-8]. Although the majority of currently available
hESC lines were derived on MEFs, concerns about ani-
mal pathogens and immunogens in cells destined for
human therapy [4] motivated scientists to explore the
use of human fibroblasts [6,9-13]. Several reports have
indicated that human fibroblasts originating from fetal,
neonatal, and adult skin are capable of supporting self-
renewal of established hESCs [6,9-13]. However, not all
human fibroblast cell lines are equally supportive of
hESC self-renewal [12]. Transcriptome analysis of sup-
portive and nonsupportive fibroblast cell lines identified
a panel of differentially expressed proteins, including
extracellular matrix proteins and growth factors, thought
to be supportive of hESC self-renewal [14].
A number of studies have reported on the use of
human fibroblast feeder cells for derivation of new
hESC lines [7,10,12,15-18], but the field currently lacks
ready access to a GMP-compliant human feeder cell line
validated for this purpose. Furthermore, when we
embarked on the derivation of GMP-grade hESCs, we
were unable to source fibroblasts that had been pro-
duced to GMP and characterized for hESC derivation
and culture. Here we describe the production, character-
ization, and validation of a GMP-grade fibroblast line
derived from human foreskin with specific ethics
approval and consent for hESC derivation and culture.
Materials and methods
Regulation and compliance
This study was approved by the Local Research Ethics
Committee (Sunderland Research Ethics Committee)
and was licensed by the UK Human Fertilisation and
Embryology Authority. Blastocysts were obtained after
informed donor consent. Human foreskins were
obtained after parental consent. The premises for the
production of the clinical-grade fibroblast line has been
licensed by the UK Human Tissue Authority (HTA) for
testing, processing, storage, distribution, and import/
export of human tissue (HTA license number 22111).
All processes associated with the derivation, expansion,
and cryopreservation of the master cell bank (MCB) of
NclFed1A were carried out in accordance with the New-
castle University Biomanufacturing Facility Quality
Management System (QMS), which operates in accor-
dance with appropriate legislation, guidance, and regula-
tion published by the Medicines and Healthcare
products Regulatory Agency (MHRA) and the HTA. All
documentation related to the QMS and to the produc-
tion process was created and managed by using Q-Pulse
software (Gael Ltd, UK.
Derivation and expansion of human fibroblasts
We derived human foreskin fibroblasts from tissue
obtained from donors deemed to be of low risk based
on their medical history. This included healthy children
of ~6 months of age undergoing circumcision for reli-
gious reasons with no known infection or disease.
Because no vertical transmission of prions has been
documented in humans, the use of tissue from a young
child minimizes the risk of prion contamination [19].
All human tissue was transferred to the processing
laboratory in PBS. The tissue was dissociated with a
scalpel (VWR, UK) and incubated with Collagenase
Type IV (Invitrogen, USA Cat. No. 17104-019) at 37°C
for 40 minutes. Samples were washed by centrifugation
and plated in a T25 or T75 flask (TPP; Switzerland)
with either FBS growth medium (DMEM (Invitrogen,
Cat. No. 11995-065), 10% FBS (Invitrogen, Cat. No.
10099-141) and 1 × glutamine (Invitrogen, Cat. No.
25030) supplemented with 1× Pen/Strep (Invitrogen)) or
with xeno-free hESC medium; KOSR-XF (KO DMEM
(Invitrogen), 15% KnockOut Serum Replacement-Xeno-
Free (Invitrogen), 0.1 mM NEAA (Invitrogen); 0.1 mM
b-mercaptoethanol; 2 mM Glutamax; 8 ng/ml FGF2
(Invitrogen)). Cells were incubated at 37°C and 5% CO2,
medium was changed every 48 to 72 hours, and cells
were passaged when cells were confluent. Cells were
deemed confluent when the growth surface of the flask
was covered by cells (Additional file 1, Figure S1).
For passaging, the culture medium was removed from
flasks and replaced with Tryple Select (Invitrogen); the
fibroblasts were incubated for 5 minutes at 37°C. The
cells were washed by centrifugation and passaged. Cells
cultured from the pre-seed bank (PSB) to the master
cell bank (MCB) were cultured in FBS growth medium
without penicillin and streptomycin. Cells were passaged
at a ratio of 1:6 in T75, T150, or T300 flasks with an
estimated plating density of 3.5 × 104 cells/cm2). When
confluent at P5, the MCB was cryopreserved; the choice
of flask was based on the maximum number of flasks an
operator could handle in one session.
Cryopreservation of fibroblasts
Fibroblasts were dissociated with Tryple Select, washed by
centrifugation, and resuspended in freeze medium (10%
DMSO (Sigma, UK) and 90% FBS (Invitrogen)). The resus-
pended cells were aliquoted into 1-ml aliquots in 2-ml
cryovials (TPP) that were cooled by using controlled-rate
freezing (Mr Frosty; Nalgene, USA) at 1°C/min. After
cryopreservation, cell counts and viability were carried out
by using a Vi-Cell (Beckman Coulter, USA).
Inactivation of fibroblasts
Fibroblasts were inactivated by using either mitomycin
C or X-ray irradiation. For mitomyocin C inactivation,
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fibroblasts were incubated with 10 μg/ml of mitomyocin
C for 2.5 hours at 37°C and 5% CO2. The mitomyocin
C was washed out by using FBS growth medium, and
washing was repeated 7 times. Samples were incubated
overnight in the FBS growth medium and cryopreserved,
as described previously. For X-ray inactivation, fibro-
blasts were exposed to 50 Gy (Faxitron, USA). Samples
were incubated overnight and cryopreserved.
Source of human blastocysts
Embryos used to determine the efficiency of hESC deriva-
tion were donated by couples undergoing assisted-concep-
tion treatment. Embryos were produced in vitro by
conventional oocyte insemination or by intracytoplasmic
sperm injection (ICSI) and cultured in G1 medium (Vitro-
life, Sweden) for 2 to 3 days until the best-quality embryos
were selected for transfer to the uterus or for cryopreser-
vation. The embryos used in this study were cryopreserved
but were no longer required for treatment. Cryopreserva-
tion and thawing was performed by using a Vitrolife
Freeze medium (Vitrolife) and Thaw medium (Vitrolife).
Thawed embryos were cultured in G2 medium (Vitrolife)
for 3 to 4 days until they developed to the blastocyst stage.
All blastocysts, regardless of quality, were included in the
study and were randomly allocated to explantation on
three different feeder cell lines.
hESC stem cell derivation and culture
hESC derivations were carried out in a fully enclosed isola-
tor cabinet (Vitrosafe). Human blastocysts were disso-
ciated by using two insulin needles (Becton Dickinson,
USA); the inner cell mass (ICM) was removed and plated
on Cellstart (Invitrogen) with either inactivated human
foreskin fibroblasts (NclFed1A) or MEFs. Samples were
incubated in hESC medium; KOSR (KO DMEM (Invitro-
gen), 20% KnockOut Serum Replacement (Invitrogen), 0.1
mM nonessential amino acids NEAA (Invitrogen); 0.1
mM b-mercaptoethanol; 2 mM Glutamax; 8 ng/ml FGF2
(Invitrogen)) supplemented with 5% Quinns Advantage
Protein Supplement (Rochford Medical, Ltd, UK). The
plated ICMs were incubated for 3 days at 37°C, 5%CO2,
and 5%O2, and were checked daily for the presence of out-
growths. Initial hESC colonies were dissected by using
insulin needles and passaged on to fresh feeder cells in
medium that was changed every 2 to 3 days. For enzymic
passaging, once the cells became 65% to 85% confluent,
they were washed once in PBS medium and then incu-
bated for 5 to 15 minutes in Tryple Select (Invitrogen).
They were washed once with centrifugation in hESC med-
ium and passaged at a ratio of 1:3 or 1:6.
PCR analysis
RNA extraction was carried out by using Dynabeads
mRNA Direct (Invitrogen) as described in the user
manual, and cDNA was synthesized by using Super-
script III (Invitrogen). The PCR primers are described
in Additional file 2, Table S1. PCR reactions were car-
ried out by adding Biomix red (Bioline, UK), as
described in the user manual. Conditions for the PCR
were 94°C for 2 minutes, 30 × (94°C for 30 seconds,
58°C for 30 seconds, 72°C for 30 seconds), and 72°C
for 15 minutes. PCR products were run on a 1% agar-
ose gel.
Population doubling time
NclFed1A was thawed and seeded in T25 flasks. After
incubation for 48 hours, cell counts were determined by
using a Vi-Cell. This was repeated at 24-hour intervals
for 4 days. Counts were repeated 3 times for each
sample.
Estimation of the number of cells in a confluent flask
NclFed1A was passaged into 8 × T150 flasks; when
deemed confluent (Additional file 2, Figure S1), the cells
were dissociated by using Tryple Express (Invitrogen),
resuspened, and three cell counts were measured for
each flask by using a Vi-Cell. The number of cells in a
confluent flask and per square centimeter was then
determined (Additional file 2, Figure S1).
Immunostaining
hESC colonies or fibroblasts were grown on coverslips.
The cells were fixed in 4% PFA, blocked with a 10% wt/
vol milk-powder solution for 1 hour at room tempera-
ture and incubated overnight at 4°C with an anti-
NANOG human polyclonal antibody raised in goat (R
and D Systems, USA), an anti-OCT4 polyclonal anti-
body raised in rabbit (Abcam, UK), HFF-Cellect (Cellar-
tis, Sweden), or 5B5 (Abcam). The cells were washed
and incubated with either Alexa Fluor 488 donkey anti-
goat immunoglobulin (Molecular Probes, USA), Alexa
Fluor 555 donkey anti-rabbit immunoglobulin (Molecu-
lar Probes), or Alexa Fluor 488 donkey anti-mouse
immunoglobulin (Molecular Probes). Nuclear staining
was carried out by using Draq5 (Biostatus, UK). Samples
were washed 3 times before imaging. Samples were
imaged by using an inverted confocal microscope (Zeiss,
Germany).
Flow-cytometry analysis for cell-surface markers
FACS analysis was carried out as described [20]. In
brief, cells were dissociated with Tryple and incubated
for 1 hour with the fibroblast-specific marker HFF-Cel-
lect (Cellartis), and an antibody raised against either
Tra-1-60, Tra-1-81, Tra-2-54, SSEA3, or SSEA4. Cells
were washed and incubated for 30 minutes with the
appropriate secondary antibody. Analysis was carried
out by using a flow cytometer (Becton Dickinson).
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Determination of Neu5GC concentrations
Cells were treated with trifluoracetic acid at 80°C for 1
hour and derivatized by using DMB solution (7 mM
1,2-diamino-4,5-methylene dioxybenzene (Sigma); 1.4 M
acetic acid (Sigma), 0.75 M b-mercaptoethanol (Sigma),
and 18 mM sodium hydrosulfite (Sigma)) for 2 hours 30
minutes at 50°C and run on an HPLC (Dionex) by using
a C8 column (Agilent AD-LC-139, USA). Samples were
run at 0.90 ml/min in an isocratic solution of 7% metha-
nol, 9% acetic acid, and 84% water. Neu5Gc detection
was carried out by using a fluorescence detector (Dio-
nex, UK) with an excitation wavelength of 373 nm and
emission wavelength of 448 nm.
Karyotyping and genotyping
Karyotyping and genotyping were contracted to The
Doctors Laboratory, which is accredited by the National
External Quality Assessment Service (NEQAS; UK).
Statistical analysis
Analysis of variance was used to investigate the effect of
the fibroblast cell line or the passage number of fibro-
blasts on the expression of pluripotency markers in
hESCs. Χ2 analysis was used to compare fibroblast cell
lines for hESC derivation efficiency. All data are
expressed as mean ± SD. As it is envisaged that
NclFed1A will be used only as feeder cells derived from
the MCB, therefore all population-doubling data (PD)
are expressed from the MCB.
Results
Selection of culture medium
In view of immunogenic and pathogenic considerations,
our starting point was to perform preliminary experi-
ments to determine whether hESCs could be derived in
culture media free of animal products (xeno-free media).
A foreskin sample, obtained from a child being treated
for hypospadias, was divided in two sections and seeded
in a T75 flask with either FBS growth medium or
KOSR-XF, which was the only GMP-compliant xeno-
free medium available at the time. Tissue seeded in the
FBS growth medium attached within 24 hours and
fibroblasts were observed 7 days after seeding; the cells
became confluent 5 days later. By contrast, cells seeded
in the KOSR-XF medium did not attach, and fibroblast
cells were not observed. In a separate experiment, we
found that coating of culture dishes with Cellstart pro-
moted attachment of foreskin tissue in the presence of
KOSR-XF; however, it took 28 days for the cells to
become confluent. After passaging of the primary cul-
ture at a ratio of 1:3, the cells took 14 days to become
confluent. Because of the slow doubling time (estimated
to be 112 hours, based on passage time, compared with
26.7 hours for cells grown on FBS) and poor
morphology of the cells, we opted to use qualified FBS-
containing medium for subsequent culture. We selected
GMP-compliant FBS from Australia, which was
screened for adventitious agents, cell-plating efficiency,
and chemical and physical properties. However, cells
cultured in FBS have been found to contain the nonhu-
man form of sialic acid [21], which is immunogenic for
humans [22]. Our strategy for minimizing this is
described later.
Production of a GMP-grade fibroblast line
We next established a GMP-compliant process for the
derivation and production of clinical-grade fibroblasts in
accordance with the Biomanufacturing Facility Quality
Management System (QMS; Figure 1a). This included
generating 37 standard operating procedures (SOPs) and
32 record forms to cover all procedures and equipment
used in this cell line-production process. In accordance
with the QMS policies and procedures, we documented
all staff training, audits, and supplier approvals. A fully
documented quarantine and release procedure for mate-
rials used in the productions process was implemented
by the QM team. A complaints procedure with the asso-
ciated Corrective and Preventive Actions (CAPA) was
also implemented by the QM team.
Fibroblast tissue for GMP-compliant production was
obtained from a healthy 6-month-old child undergoing
circumcision for religious reasons. After excision, the
foreskin tissue was transferred from the operating thea-
ter to a QM-controlled primary cell-culture laboratory
through a documented chain of custody (Figure 1b).
The tissue sample was split into two sections (CPR/
HGP/Ncl/Fed1a and CPR/HGP/Ncl/Fed1b), and each
section was seeded into a T75 flask. Attachment and
outgrowth of cells with fibroblast morphology were
observed by day 4. Both sublines became confluent
within14 days of seeding and were cultured to P1 or P2
for production of a pre-seed bank (PSB) consisting of
eight vials of each subline. After microbial and myco-
plasma clearance, and validation for hESC culture and
derivation (see later), the subline CPR/HGP/Ncl/Fed1A
(NclFed1A) was transferred to the Grade B clean-room
suite for onward culture.
To establish a master cell bank (MCB) of NclFed1A,
cells from the PSB were seeded at an estimated density
of 3.5 × 104 cells/cm2 and grown to confluence before
being passaged at an equivalent density until P5 (equiva-
lent to eight population doublings (PDs) from the PSB),
when they were frozen to form an MCB consisting of
200 vials containing 7.5 × 106 cells/vial. Seven vials were
used to test for bacterial and fungal contaminants,
mycoplasma, and retroviruses by using Eu Pharmaco-
poeia methods (Table 1). In view of the large quantity
of cells required for viral testing, an additional two vials
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Figure 1 Derivation of the clinical grade fibroblast line NclFed1A. (a) A detailed description of the Quality Management System (QMS)
required for processing cells to good manufacturing practice (GMP; passaging of NclFed1A). (b) Schematic showing the general processes
involved in deriving a fibroblast cell line under the control of GMP. “Upstream” includes all processes that are in place before the derivation and
expansion of the fibroblast line. “Downstream” refers to biosafety and functionality testing of the line.
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of the MCB were passaged to produce 1.9 × 108 cells,
which were cryopreserved and tested for bovine viruses
(according to 9CFR guidelines (Section 113.46, 113.47
and 113.53)), and for human viruses (HIV1 and 2 pro-
virus, HTLV1 and 2 provirus, HAV, HBV, HCV, HHV6,
HHV7, HHV8, hCMV, EBV, SV40, and B19).
Characterization of NclFed1A as a fibroblast cell line
NclFed1A had a typical fibroblast morphology (Figure
2a) and stained positive for HFF-Cellect (Figure 2b), a
mouse monoclonal antibody derived from mice immu-
nized with human foreskin fibroblasts. In addition,
immunofluorescence labeling showed positive staining
for 5B5 (Figure 2c), a fibroblast-specific protein required
for triple-helix formation in collagen [23]. Moreover,
flow-cytometry analysis showed that NclFed1A was
positive for proteins previously found to be expressed in
fibroblasts, including CD90 [24-26]; CD166 [25], and
CD44 [27] (Figure 2d through 2f).
For the purposes of traceability, we determined the
DNA profile of the cell line by using 15 polymorphic
autosomal DNA markers (Additional file 2, Table S2).
Karyoptype analysis of the MCB showed a normal male
karyotyped 46XY (Figure 2g). Further to characterize
the cell line and to assess the time to confluence during
routine culture, we measured the doubling time of
NclFed1A across several passages. A mean doubling
time of 26.7 ± 13 hours was calculated for cells thawed
from the PSB, the MCB, 10 population doublings from
the MCB (PD10), and 28 population doublings from the
MCB (PD28). No significant difference in doubling time
was found between samples (Figure 2h). Subsequent
observations indicated that cell senescence did not
become apparent until 54 population doublings from
the MCB.
NclFed1A supports hESC derivation and culture
As an initial assessment, we tested NclFed1A for expres-
sion of genes predicted to be important for the mainte-
nance of hESC pluripotency [14]. By using PCR analysis,
we tested NclFed1A at the PSB, MCB, PD10, and PD28
for expression of transcripts encoding extracellular
matrix proteins Col1A1, Col3A1, Col5A1, fibronectin 1,
heparin sulfate proteoglycan, and hyaluron synthase 2
(HAS2), as well as the ligands and growth factors FGF2,
IGFBP3, ADAM33, and Grem1. With the exception of
Col5A1 and ADAM33, we found that all factors were
expressed at PSB, MCB, and PD10 (Table 2). By con-
trast, at PD28, only Col1A, HAS2, IGFBP3, and Grem1
were detected.
We next tested the ability of NclFed1A to support
hESC derivation from blastocysts. The efficiency of deri-
vation was compared with MEFs from CF1 and C57BL6
mouse strains; both of which have been reported to be
supportive of hESC derivation and/or culture [28-30].
After explantation of the ICM onto the inactivated
fibroblasts, the proportion of outgrowths for NclFed1A
was similar to that observed on MEFs (five of nine
(NclFed1A) versus four of 10 (CF1) and two of eight
(C57Bl6)). Subsequently, hESC colonies were observed
on all fibroblast lines between days 6 and 11 (three of
nine (NclFed1A) versus three of 10 (CF1) and one of
eight (C57Bl6)) (Figure 3a). To test the ability of
NclFed1A to support the proliferation and pluripotency
of hESCs, two of the lines derived (Ncl12 and Ncl(R)14)
on NclFed1A were cultured to P24. Both cell lines
retained normal hESC morphology and, at P24,
expressed OCT4 and NANOG (Figure 3b).
Further qualification of NclFed1A for use a feeder cell
line for hESCs was conducted by the UK Stem Cell
Bank (UKSCB) as follows. The hESC lines Shef1, RH-1,
HUES-9, and NCL5 were cultured in parallel on inacti-
vated MEFs (MEF), neonatal foreskin fibroblasts
(HDFn), fetal lung fibroblast (MRC-5), and NclFed1A.
After five passages, the percentage of cells expressing
the pluripotent surface markers was determined with
flow cytometry. No difference was found in the propor-
tion of cells expressing Tra-1-60, Tra-1-81, Tra-2-54,
SSEA3, and SSEA4 between NclFed1A, MEFs, and
HDFn; however, a greater proportion of hESCs cultured
on NclFed1A expressed Tra-1-60 than did those on
MRC-5 (P < 0.05; Figure 3c and Additional file 2, Table
S3). No significant differences were noted between
NclFed1A at PD8 to PD28 in the proportion of hESCs
Table 1 Biosafety tests carried out on the NclFed1A master cell bank
Test Reference Test
result
Sterility test and qualification of test article by direct inoculation method [38] Negative
Test for Mycoplasma spp.(Including mycoplasmastasis assay) [38] Negative
Retroviruses: detection of reverse transcriptase (F-Pert assay) [39-47] Negative
Detection of human viral pathogens (HIV 1 and 2 provirus, HTLV 1 and
2 provirus, HAV, HBV, HCV, HHV-6, HHV-7, HHV-8, hCMV, EBV, SV40 and B19) by real-time polymerase chain reaction
(PCR).
[48] Negative
Detection of bovine viruses with in vitro adventitious assay according to 9CFR Guidelines [43,45,47,49-52] Negative
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Figure 2 Characterization of NclFed1A as fibroblasts. (a) NclFed1A has a normal fibroblast morphology. (b) Cells were positive for HFF-
Cellect, a mouse monoclonal antibody derived from mice immunized with human foreskin fibroblasts (scale bar, 50 μm). (c) Cells were positive
for the fibroblast marker 5B5 required for triple-helix formation in collagen (scale bar, 50 μm). (d-f) Histograms from flow cytometry showing the
proportion of cells positive for (d) CD90, (e) CD166, and (f) CD44. (g) NclFed1A had a normal male karyotype. (h) The doubling time of
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expressing the pluripotent surface markers Tra1-60,
Tra1-81, Tra-2-54, SSEA3, and SSEA4 after five pas-
sages (Figure 3d and Additional file 2, Table S4). How-
ever, by PD38, a significant decline was apparent in the
proportion of hESC cells expressing Tra-1-81 and
SSEA4 compared with hESCs cultured on feeders at
PD8 (P < 0.05; Figure 3e, f, and Additional file 2, Table
S4). Consistent with this, hESCs cultured on NclFed1A
at PD38 showed morphologic signs of differentiation
(Figure 3e and 3f). Thus, NclFed1A remains supportive
of hESC self-renewal up to PD28. This is surprising,
given that expression of the hESC supportive factors
was greatly reduced at an equivalent number of popula-
tion doublings (Table 2).
Neu5Gc content is reduced after culture in xeno-free
medium
Given that cells cultured in the presence of animal-
derived products have been reported to contain the
nonhuman form of sialic acid (Neu5Gc), which is
immunogenic for humans [31], we determined whether
the sialic acid content of NclFed1A could be reduced by
transferring the cells to a xeno-free medium (KOSR-XF)
before using them as feeder cells for hESCs. The con-
centration of Neu5Gc was measured with HPLC at 2-
day intervals for 6 days after transfer of inactivated
NclFed1A cells into KOSR-XF medium. By day 2, a 64%
reduction in Neu5Gc content was found, compared with
inactivated fibroblasts cultured in xeno-containing hESC
(KOSR) medium at day 2 (Figure 4a). No significant
further reduction was observed for 6 days.
We then tested whether the level of Neu5Gc could be
further reduced by culturing NclFed1A in KOSR-XF
medium for 6 days before inactivation. This strategy
resulted in a 93% reduction in Neu5Gc concentration
(0.63 versus 0.04 pMol/1 million cells; Figure 4b and 4c)
compared with cells grown in xeno-containing KOSR
medium. Even though the fibroblasts proliferated slowly
in KOSR-XF, this did not affect their ability to support
self-renewal of hESCs after inactivation (data not
shown).
Discussion
Here we report on the successful production of a GMP-
grade fibroblast line (NclFed1A), characterized for use
as feeder cells for the derivation and long-term culture
of hESCs, as summarised in Table 3. The efficiency of
hESC derivation from human blastocysts was compar-
able to that of MEF lines. In addition, NclFed1A com-
pared favorably with commercially available fibroblasts
in supporting proliferation and pluripotency of a num-
ber of widely used hESC lines. To the best of our
knowledge, this is the first report that describes the pro-
duction of a GMP-grade fibroblast line characterized for
the derivation and culture of hESCs.
Our tissue of choice was foreskin fibroblasts, as it is
easily accessible from healthy individuals undergoing cir-
cumcisions for religious practices. Furthermore, as the
tissue was sourced from a child of about 6 months old,
it is in compliance with the US Food and Drug Admin-
istration (FDA) regulations relating to the risk of prion
contamination of primary tissue sourced from donors in
the UK born before 1996 [32]. As further precautionary
measures to minimize the transmission of infectious
agents, we selected healthy low-risk donors based on
their medical histories. Further preventive measures may
include donor-blood biosafety testing that is routinely
carried out for organ transplants and when tissue/cells
are immediately transferred to a recipient. Because
NclFed1A is intended to support the proliferation of
hESCs and not for direct therapeutic use, we confined
our biosafety testing to the cell line.
Although the use of xeno-containing media is not
incompatible with GMP compliance, culturing in xeno-
containing media results in increased sialic acid
(Neu5Gc) concentration and the risk of immune rejec-
tion of hESC derivatives [31]. However, our attempts to
derive a feeder cell line in the absence of animal compo-
nents were hampered by the lack of a suitable xeno-free
GMP-grade culture medium. We therefore opted to use
FBS-containing medium, which has previously been
used to produce cells intended for therapeutic use. For
example, FBS-containing media have been used for sev-
eral years for keratinocyte-based human therapies [33].
More recently, clinical grade hESC lines have been pro-
duced by using xeno-containing medium [15]. To mini-
mize the risks associated with FBS, we used qualified
FBS sourced from Australia that has had no reported
cases of BSE, and tested the cell line for pathogens and
retroviruses in accordance with Eu Pharmacopoeia.
Table 2 Presence (✓) and absence (x) of transcripts in NclFed1A at PSB, MCB, PD10, and PD28 that have been
predicted to support hESC culture
NclFed1A Col1A1 Col3A1 Col5A1 FN1 HSPG2 HAS2 IGFBP3 FGF2 ADAM33 Grem1
PSB ✓ ✓ X ✓ ✓ ✓ ✓ ✓ X ✓
MCB ✓ ✓ X ✓ ✓ ✓ ✓ ✓ X ✓
PD10 ✓ ✓ X ✓ ✓ ✓ ✓ ✓ X ✓
PD28 ✓ X X X X ✓ ✓ X X ✓
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Figure 3 NclFed1A supports human embryonic stem cell (hESC) derivation and culture. (a) The proportion of outgrowths and hESC lines
produced by using NclFed1A and MEFS (derived from CF1 and C57Bl6 strains) as feeder cells. (b) hESCs cultured on NclFed1A for 24 passages
were positive for the pluripotency markers NANOG and OCT4 (scale bar, 100 μm). (c) A greater proportion of cells expressed Tra-1-60 when
cultured on NclFed1A than on MRC-5 (P < 0.05); no significant difference was noted between the expression of pluripotency markers after
culture on NclFed1A, iHDFn, and iMEF. (d) The expression of pluripotency markers was similar after culture on NclFed1A at PD8, PD18, and PD28;
at PD38, fewer cells expressed Tra-1-81 and SSEA4 (P < 0.05). (e) hESCs cultured on NclFed1A at P15 had normal hESC morphology. (f) hESCs
cultured on NclFed1A at PD38 showed signs of differentiation (arrows).
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Figure 4 High-performance liquid chromatography (HPLC) analysis showing the concentration of Neu5Gc in cells cultured in xeno-free
human embryonic stem cell (hESC) medium (KOSR-XF) and xeno-containing medium (KOSR). (a) The concentration of Neu5Gc in
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These results were negative, so we tested whether a
reduction in immunogenicity could be achieved after
transfer of the feeder cells into xeno-free medium. In
agreement with previous studies, we found that the con-
centration of Neu5Gc was greatly reduced by culturing
cells in KOSR-XF medium [31,34]. A more substantial
effect (93% reduction) was achieved when cells were
transferred to the KOSR-XF medium before inactivation.
Tests for mRNA expression of proteins thought to be
supportive of self-renewal [14] revealed that eight of the
10 transcripts predicted to support hESCs [14] were pre-
sent up to PD10 from the MCB. By contrast, only four
(Col1a, HAS2, IGFBP3, and Grem1) were detected at
PD28. This indicates that the gene-expression profile
changes during the repeated passage of dermal fibroblasts
derived from primary tissue. Surprisingly, this did not
have any detectable effect on the ability of NclFed1A to
support hESC self-renewal. This implies that feeder cell-
derived Col3A1, Col5A1, ADAM33, FGF2, fibronectin,
and heparin sulfate proteoglycan is not essential for main-
tenance of hESC lines, by using our culture conditions.
Finally, although significant progress has been made in
the production of defined matrices such as laminin
[35,36], vitronectin [37], and fibronectin [35] to support
self-renewal of hESCs, a reliable feeder-free system for
hESC derivation has not yet been reported. Thus, in the
short term, at least, production of new clinical grade
hESC lines will require a source of GMP-compliant fee-
der cells validated for this purpose. Importantly, specific
consent was obtained for the use of NclFed1A as a fee-
der cell line for hESCs and for iPSCs. Consent was also
obtained to generate iPSCs from this cell line. NclFed1A
is available to the research and clinical community.
Conclusions
To the best of our knowledge, no consistent reports
exist on the derivation of new hESC lines by using fee-
der-free systems; therefore, the next generation of
GMP-grade hESCs will require feeder cells. NclFed1A
was derived because of a lack of readily available GMP-
grade fibroblasts that have been consented for and vali-
dated to support hESC and iPSC culture. We showed
that NclFed1A was comparable to non-GMP-grade
fibroblasts widely used to support hESC derivation and
culture. This cell line is available to the research and
clinical community.
Additional material
Additional file 1: Figure S1. Images of NclFed1A showing (a) about
15% confluent, (b) about 60% confluent, and (c) 100% confluent. (d) The
number of cells per square centimeter in a confluent flask was
determined by counting cells with a Vi-Cell (Beckman Coulter), in eight
different confluent T150 flasks. Counts were repeated 3 times for each
flask.
Additional file 2: Table S1. PCR primers used to determine the
presence of transcripts in NclFed1A that are predicted to be supportive
of hESC cultures. Table S2. STR analysis with genotype copy number for
allele 1 and 2. Table S3. The expression of pluripotency markers
determined by FACs analysis after culture of four hESC lines for five
passages on four different fibroblasts lines. Table S4. The expression of
pluripotency markers determined by FACs analysis after culture of hESC
lines for five passages on NclFed1A at P10, P15, P20, and P25.
Abbreviations
FBS: fetal bovine serum; FDA: Food and Drug Administration; GMP: good
manufacturing practice; hESC: human embryonic stem cell; HFEA: Human
Fertility and Embryo Authority; HTA: Human Tissue Authority; iPSC: induced
pluripotent stem cell; KOSR: KnockOut serum replacement; KOSR-XF:
KnockOut serum replacement xeno-free; MCB: master cell bank; mEFs:
Table 3 The characteristics of NclFed1A
Characteristics Result
Characterization of NclFed1A
Expression of fibroblast markers Expresses HFFCellect, 5B5, CD90, CD44,
and CD160
Karyology Normal male karyotype
Identification STR analysis determined
Cell-doubling time 26.7 ± 13 hours
Biosafety testing on the MCB
Sterility Not detected
Mycoplasma Not detected
Retroviruses Not detected
Human viruses HIV 1 and 2 provirus, HTLV 1 and 2 provirus, HAV, HBV, HCV, HHV-6, HHV-7, HHV-8,
hCMV, EBV, SV40, and B19
Not detected
Bovine viruses (9CFR) Not detected
Ability to support hESCs
Ability to support hESC derivation 33% (three of nine blastocysts plated)
Ability to support hESC culture Yes (up to 28 population doublings from
the MCB)
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mouse embryonic fibroblasts; MHRA: Medicines and Healthcare Products
Regulatory Agency; Neu5Gc: N-glycolylneuraminic acid; NclFed1a: CPR/HGP/
Ncl/Fed1A; P: passage; PDs: population doublings from the MCB; PSB:
preseed bank.
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